{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:26:17Z","timestamp":1774124777148,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10571-020-01001-2","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:50:03Z","timestamp":1605243003000},"page":"1077-1084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Opioid Interactions of the Antipsychotic Medications Risperidone and Amisulpride in Mice and Their Potential Use in the Treatment of Other Non-Psychotic Medical Conditions"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-0693","authenticated-orcid":false,"given":"Shaul","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7114-339X","authenticated-orcid":false,"given":"Chaim G.","family":"Pick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"1001_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1601-5215.2007.00193.x","volume":"19","author":"L Atik","year":"2007","unstructured":"Atik L, Konuk N, Akay O, Ozturk D, Erdogan A (2007) Pain perception in patients with bipolar disorder and schizophrenia. Acta Neuropsychiatrica 19:284\u2013290. https:\/\/doi.org\/10.1111\/j.1601-5215.2007.00193.x","journal-title":"Acta Neuropsychiatrica"},{"key":"1001_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11920-010-0107-9","volume":"12","author":"S Barnow","year":"2010","unstructured":"Barnow S, Arens EA, Sieswerda S, Dinu-Biringer R, Spitzer C, Lang S (2010) Borderline personality disorder and psychosis: a review. Curr Psychiatry Rep 12:186\u2013195. https:\/\/doi.org\/10.1007\/s11920-010-0107-9","journal-title":"Curr Psychiatry Rep"},{"key":"1001_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00213-008-1336-z","volume":"202","author":"A Becker","year":"2009","unstructured":"Becker A, Grecksch G, Zernig G, Landstaetter E, Heimek C, Schmitt U (2009) Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. Psychopharmacology 202:579\u2013587. https:\/\/doi.org\/10.1007\/s00213-008-1336-z","journal-title":"Psychopharmacology"},{"key":"1001_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/AJP.0b013e318192be97","volume":"25","author":"O Bonnot","year":"2009","unstructured":"Bonnot O, Anderson GM, Cohen D, Willer JC, Tordjman S (2009) Are patients with schizophrenia insensitive to pain? A reconsideration of the question. Clin J Pain 25:244\u2013252. https:\/\/doi.org\/10.1097\/AJP.0b013e318192be97","journal-title":"Clin J Pain"},{"key":"1001_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0014-2999(84)90085-2","volume":"107","author":"JH Boublik","year":"1985","unstructured":"Boublik JH, Funder JW (1985) Interaction of dopamine receptor ligands with subtypes of the opiate receptor. Eur J Pharmacol 107:11\u201316. https:\/\/doi.org\/10.1016\/0014-2999(84)90085-2","journal-title":"Eur J Pharmacol"},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0014-2999(01)01484-4","volume":"432","author":"MP Castelli","year":"2001","unstructured":"Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L (2001) (-)S amisulpride binds with high affinity to cloned dopamine D3 and D2 receptors. Euro J Pharm 432:143\u2013147. https:\/\/doi.org\/10.1016\/s0014-2999(01)01484-4","journal-title":"Euro J Pharm"},{"key":"1001_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/j.1875-9114.1994.tb02819.x","volume":"14","author":"LJ Cohen","year":"1994","unstructured":"Cohen LJ (1994) Risperidone. Pharmacotherapy 14:253\u2013265","journal-title":"Pharmacotherapy"},{"issue":"12","key":"1001_CR8","doi-asserted-by":"publisher","first-page":"e52633","DOI":"10.1371\/journal.pone.0052633","volume":"7","author":"F Collu","year":"2012","unstructured":"Collu F, Ceccarelli M, Ruggerone P (2012) Exploring binding properties of agonists interacting with a d-opioid receptor. PLoS One 7(12):e52633. https:\/\/doi.org\/10.1371\/journal.pone.0052633","journal-title":"PLoS One"},{"key":"1001_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drugalcdep.2005.05.009","volume":"81","author":"WM Compton","year":"2006","unstructured":"Compton WM, Volkow ND (2006) Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 81:103\u2013107. https:\/\/doi.org\/10.1016\/j.drugalcdep.2005.05.009","journal-title":"Drug Alcohol Depend"},{"key":"1001_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00004850-199907000-00002","volume":"14","author":"C Coulouvrat","year":"1999","unstructured":"Coulouvrat C, Dondey-Nouvel L (1999) Safety of amisulpride: a review of 11 clinical studies. Int Clin Psychopharm 14:209\u2013218. https:\/\/doi.org\/10.1097\/00004850-199907000-00002","journal-title":"Int Clin Psychopharm"},{"key":"1001_CR11","first-page":"74","volume":"72","author":"FE D'Amour","year":"1941","unstructured":"D\u2019Amour FE, Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74\u201379","journal-title":"J Pharmacol Exp Ther"},{"key":"1001_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.pscychresns.2010.05.003","volume":"183","author":"C de la Fuente-Sandoval","year":"2010","unstructured":"de la Fuente-Sandoval C, Favila R, Gomez-Martin D, Pellicer F, Graff-Guerrero A (2010) Functional magnetic resonance imaging response to experimental pain in drug-free patients with schizophrenia. Psychiatry Res Neuroimaging 183:99\u2013104. https:\/\/doi.org\/10.1016\/j.pscychresns.2010.05.003","journal-title":"Psychiatry Res Neuroimaging"},{"key":"1001_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.biopsych.2015.08.001","volume":"79","author":"SH Gage","year":"2016","unstructured":"Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 79:549\u2013556. https:\/\/doi.org\/10.1016\/j.biopsych.2015.08.001","journal-title":"Biol Psychiatry"},{"key":"1001_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00734995","volume":"3","author":"S Gentleman","year":"1983","unstructured":"Gentleman S, Parenti M, Neff NH, Pert CB (1983) Inhibition of dopamine-activated adenylate cyclase and dopamine binding by opiate receptors in rat striatum. Cell Mol Neurobiol 3:17\u201326. https:\/\/doi.org\/10.1007\/BF00734995","journal-title":"Cell Mol Neurobiol"},{"key":"1001_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40263-014-0209-8","volume":"28","author":"S Glasner-Edwards","year":"2014","unstructured":"Glasner-Edwards S, Mooney LJ (2014) Methamphetamine psychosis: epidemiology and management. CNS Drugs 28:1115\u20131126. https:\/\/doi.org\/10.1007\/s40263-014-0209-8","journal-title":"CNS Drugs"},{"key":"1001_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/00003495-199448020-00009","volume":"48","author":"S Grant","year":"1994","unstructured":"Grant S, Fitton A (1994) Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48:253\u2013273. https:\/\/doi.org\/10.2165\/00003495-199448020-00009","journal-title":"Drugs"},{"key":"1001_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0014-2999(80)90515-4","volume":"67","author":"JLK Hylden","year":"1980","unstructured":"Hylden JLK, Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313\u2013316","journal-title":"Eur J Pharmacol"},{"key":"1001_CR18","unstructured":"IASP terminology part III: pain terms, a current list with definitions and notes on usage (pp 209\u2013214) classification of chronic pain, second edition, IASP task force on taxonomy, edited by H. Merskey and N. Bogduk, IASP Press, Seattle, \u00a91994. https:\/\/www.iasp-pain.org\/PublicationsNews\/Content.aspx?ItemNumber=1957&navItemNumber=677"},{"issue":"6408","key":"1001_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.aau1184","volume":"361","author":"H Jalal","year":"2018","unstructured":"Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS (2018) Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 361(6408):1\u20136. https:\/\/doi.org\/10.1126\/science.aau1184","journal-title":"Science"},{"key":"1001_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.psychres.2005.09.004","volume":"142","author":"T Jochum","year":"2006","unstructured":"Jochum T, Letzsch A, Greiner W, Wagner G, Sauer H, Bar KJ (2006) Influence of antipsychotic medication on pain perception in schizophrenia. Psychiatry Res 142:151\u2013156. https:\/\/doi.org\/10.1016\/j.psychres.2005.09.004","journal-title":"Psychiatry Res"},{"key":"1001_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0022-3956(94)90023-X","volume":"28","author":"S Lautenbacher","year":"1994","unstructured":"Lautenbacher S, Krieg JC (1994) Pain perception in psychiatric disorders: a review of the literature. J Psychiatr Res 28:109\u2013122","journal-title":"J Psychiatr Res"},{"key":"1001_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1185\/030079902125001083","volume":"18","author":"Y Lecrubier","year":"2002","unstructured":"Lecrubier Y (2002) Amisulpride: progress and outcomes. Curr Med Res Opin 18:18\u201322","journal-title":"Curr Med Res Opin"},{"key":"1001_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","volume":"159","author":"S Leucht","year":"2002","unstructured":"Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta analysis of randomized controlled trials. Am J Psych 159:180\u2013190. https:\/\/doi.org\/10.1176\/appi.ajp.159.2.180","journal-title":"Am J Psych"},{"key":"1001_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/0149-2918(95)80105-7","volume":"17","author":"E Lindstrom","year":"1995","unstructured":"Lindstrom E, Eriksson B, Hellgren A, Von Knorring L, Eberhard G (1995) Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 17:402\u2013412","journal-title":"Clin Ther"},{"key":"1001_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.schres.2012.10.038","volume":"143","author":"C Linnman","year":"2013","unstructured":"Linnman C, Coombs G 3rd, Goff DC, Holt DJ (2013) Lack of insula reactivity to aversive stimuli in schizophrenia. Schizophr Res 143:150\u2013157. https:\/\/doi.org\/10.1016\/j.schres.2012.10.038","journal-title":"Schizophr Res"},{"issue":"Suppl. 1 Part A","key":"1001_CR26","doi-asserted-by":"publisher","first-page":"92A","DOI":"10.1097\/00002826-199201001-00049","volume":"15","author":"SR Mader","year":"1992","unstructured":"Mader SR (1992) Risperidone: clinical development: North American results. Clin Neuropharmacol 15(Suppl. 1 Part A):92A-93A","journal-title":"Clin Neuropharmacol"},{"key":"1001_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJM195903192601203","volume":"260","author":"WE Marchand","year":"1959","unstructured":"Marchand WE, Sarota B, Marble HC, Leary TM, Burbank CB, Bellinger MJ (1959) Occurrence of painless acute surgical disorders in psychotic patients. N Engl J Med 260:580\u2013585","journal-title":"N Engl J Med"},{"key":"1001_CR28","first-page":"287","volume":"18","author":"AGI Maremmani","year":"2014","unstructured":"Maremmani AGI, Rovai L, Rugani F, Bacciardi S, Dell\u2019Osso L, Maremmani I (2014) Substance abuse and psychosis. The strange case of opioids. Eur Rev Med Pharmacol Sci 18:287\u2013302","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1001_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/alcalc\/agx090","volume":"53","author":"B Masood","year":"2018","unstructured":"Masood B, Lepping P, Romanov D, Poole R (2018) Treatment of alcohol-induced psychotic disorder (Alcoholic Hallucinosis)\u2014a systematic review. Alcohol Alcohol 53:259\u2013267. https:\/\/doi.org\/10.1093\/alcalc\/agx090","journal-title":"Alcohol Alcohol"},{"key":"1001_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/00004714-200212000-00004","volume":"22","author":"MJ Muller","year":"2002","unstructured":"Muller MJ, Wetzel H, Erich FX, Rein W, Puech A, Benkert O (2002) Dose-related effects of amisulpride on five dimentions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychophsrmacol 22:554\u2013560. https:\/\/doi.org\/10.1097\/00004714-200212000-00004","journal-title":"J Clin Psychophsrmacol"},{"key":"1001_CR31","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S0140-6736(09)62061-4","volume":"375","author":"H Murakami","year":"2010","unstructured":"Murakami H, Tamasawa M, Yamashita M, Takayasu S, Nigawara T, Matsui J, Suda T (2010) Altered pain perception in schizophrenia. Lancet 375:864. https:\/\/doi.org\/10.1016\/S0140-6736(09)62061-4","journal-title":"Lancet"},{"key":"1001_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/00002018-199819020-00006","volume":"19","author":"C Nelson-Piercy","year":"1998","unstructured":"Nelson-Piercy C (1998) Treatment of nausea and vomiting in pregnancy: when should it be treated and what can be safely taken? Drug Saf 19:155\u2013164. https:\/\/doi.org\/10.2165\/00002018-199819020-00006","journal-title":"Drug Saf"},{"key":"1001_CR33","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"1001_CR34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/0885-3924(94)90201-1","volume":"9","author":"RB Patt","year":"1994","unstructured":"Patt RB, Proper G, Reddy S (1994) The neuroleptics as adjuvant analgesics. J Pain Symptom Manage 9:446\u2013453","journal-title":"J Pain Symptom Manage"},{"key":"1001_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0014-2999(88)90680-2","volume":"149","author":"D Paul","year":"1988","unstructured":"Paul D, Pasternak GW (1988) Differential blockade by naloxonazine of two mu opiate actions: analgesia and inhibition of gastrointestinal transit. Eur J Pharmacol 149:403\u2013404","journal-title":"Eur J Pharmacol"},{"key":"1001_CR36","first-page":"769","volume":"255","author":"D Paul","year":"1990","unstructured":"Paul D, Levison JA, Howard DH, Pick CG, Hahn EF, Pasternak GW (1990) Naloxone benzoylhydrazone (NalBzoH) analgesia. J Pharmacol Exp Ther 255:769\u2013774","journal-title":"J Pharmacol Exp Ther"},{"key":"1001_CR37","first-page":"73","volume":"280","author":"GH Perrault","year":"1997","unstructured":"Perrault GH, Depoortere R, Morel E, Sanger DJ, Scatton B (1997) Psychopharmacological profile of amisulpride. J Pharmacol Experim Therap 280:73\u201382","journal-title":"J Pharmacol Experim Therap"},{"key":"1001_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pain.2007.11.007","volume":"138","author":"S Potvin","year":"2008","unstructured":"Potvin S, Marchand S (2008) Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a systematic quantitative review of experimental studies. Pain 138:70\u201370. https:\/\/doi.org\/10.1016\/j.pain.2007.11.007","journal-title":"Pain"},{"key":"1001_CR39","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jpsychires.2007.11.001","volume":"42","author":"S Potvin","year":"2008","unstructured":"Potvin S, Stip E, Tempier A, Pampoulova T, Bentaleb LA, Lalonde P, Lipp O, Goffaux P, Marchand S (2008) Pain perception in schizophrenia: no changes in diffuse noxious inhibitort controls (DNIC) but a lack of pain sensitization. J Psychiatr Res 42:1010\u20131016. https:\/\/doi.org\/10.1016\/j.jpsychires.2007.11.001","journal-title":"J Psychiatr Res"},{"key":"1001_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1049909112441241","volume":"30","author":"E Prommer","year":"2012","unstructured":"Prommer E (2012) Olanzapine: palliative medicine update. Am J Hospice Palliat Med 30:75\u201382. https:\/\/doi.org\/10.1177\/1049909112441241","journal-title":"Am J Hospice Palliat Med"},{"key":"1001_CR41","first-page":"83","volume":"280","author":"H Schoemaker","year":"1997","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83\u201397","journal-title":"J Pharmacol Exp Ther"},{"key":"1001_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0924-977X(96)00031-4","volume":"6","author":"S Schreiber","year":"1996","unstructured":"Schreiber S, Backer MM, Yanai J, Pick CG (1996) The antinociceptive effect of fluvoxamine. Eur Neuropsychopharmacol 6:281\u2013284. https:\/\/doi.org\/10.1016\/S0924-977X(96)00031-4","journal-title":"Eur Neuropsychopharmacol"},{"key":"1001_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0304-3940(97)00345-5","volume":"228","author":"S Schreiber","year":"1997","unstructured":"Schreiber S, Backer MM, Weizman R, Pick CG (1997) Augmentation of opioids analgesia by the atypical antipsychotic drug risperidone in mice. Neurosci Lett 228:25\u201328. https:\/\/doi.org\/10.1016\/S0304-3940(97)00345-5","journal-title":"Neurosci Lett"},{"key":"1001_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0091-3057(99)00107-0","volume":"64","author":"S Schreiber","year":"1999","unstructured":"Schreiber S, Getslev V, Weizman R, Pick CG (1999) The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharm Biochem Behav 64:75\u201380. https:\/\/doi.org\/10.1016\/S0091-3057(99)00107-0","journal-title":"Pharm Biochem Behav"},{"key":"1001_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1090-3801(02)00146-5","volume":"7","author":"S Schreiber","year":"2003","unstructured":"Schreiber S, Shmueli D, Grunhaus L, Dolberg OT, Feldinger E, Magora F, Shapira SC (2003) The influence of electroconvulsive therapy (ECT) on pain threshold and pain tolerance in major depression patients before, during and after treatment. Eur J Pain 7:419\u2013424. https:\/\/doi.org\/10.1016\/S1090-3801(02)00146-5","journal-title":"Eur J Pain"},{"key":"1001_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000500162","volume":"52","author":"J Seikkula","year":"2019","unstructured":"Seikkula J (2019) Psychosis is not illness but a survival strategy in severe stress: a proposal for an addition to a phenomenological point of view. Psychopathology 52:143\u2013150. https:\/\/doi.org\/10.1159\/000500162","journal-title":"Psychopathology"},{"key":"1001_CR47","first-page":"452","volume":"118","author":"Y Shir","year":"1990","unstructured":"Shir Y, Shenkman Z, Kaplan L (1990) Neuropathic pain unrelieved by morphine, alleviated by haloperidol. Harefuah 118:452\u2013454","journal-title":"Harefuah"},{"key":"1001_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-phartmtox-010617-052534","volume":"58","author":"P Skolnick","year":"2018","unstructured":"Skolnick P (2018) The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol 58:143\u2013159. https:\/\/doi.org\/10.1146\/annurev-phartmtox-010617-052534","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1001_CR49","first-page":"255","volume":"246","author":"AE Takemori","year":"1988","unstructured":"Takemori AE, Ho BY, Naeseth JS, Portoghese PS (1988) Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 246:255\u2013258","journal-title":"J Pharmacol Exp Ther"},{"key":"1001_CR50","unstructured":"The Joint Commission on Accreditation of Healthcare Organizations Pain Standards for 2001. https:\/\/www.jcaho.com\/standard\/pm.html (last accessed May 30, 2020)."},{"key":"1001_CR51","volume-title":"Symptom control in far advanced cancer: pain relief","author":"RG Twycross","year":"1983","unstructured":"Twycross RG, Lack SA (1983) Symptom control in far advanced cancer: pain relief. Pitman, London"},{"key":"1001_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejphar.2003.08.049","volume":"478","author":"T Weizman","year":"2003","unstructured":"Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S (2003) The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol 478:155\u2013159. https:\/\/doi.org\/10.1016\/j.ejphar.2003.08.049","journal-title":"Eur J Pharmacol"},{"key":"1001_CR53","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/j.1532-2149.2013.00310.x","volume":"17","author":"A Wojakiewicz","year":"2013","unstructured":"Wojakiewicz A, Januel D, Braha S, Prkachin K, Danziger N, Bouhassira D (2013) Alteration of pain recognition in schizophrenia. Eur J Pain 17:1385\u20131392. https:\/\/doi.org\/10.1002\/j.1532-2149.2013.00310.x","journal-title":"Eur J Pain"}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-020-01001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10571-020-01001-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-020-01001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T21:22:07Z","timestamp":1698355327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10571-020-01001-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s10571-020-01001-2","relation":{},"ISSN":["0272-4340","1573-6830"],"issn-type":[{"value":"0272-4340","type":"print"},{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}